AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4009965 — intervention group
Group type: EXPERIMENTAL
Intervention: slow-release nifedipine (20 mg twice daily)
Number of subjects: 20
Study 4009965 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 30032885 — intervention group
Group type: COMPARATOR
Intervention: Ketamine 0 mg kg‐1
Number of subjects: 50
Study 30032885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.25 mg kg‐1
Number of subjects: 50
Study 30032885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg kg‐1
Number of subjects: 50
Study 30032885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg kg‐1
Number of subjects: 50
Study 30032885 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of mean arterial pressure
Number of subjects: 50
Study 26867863 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time medication monitoring (medication dispenser for ribavirin intake)
Number of subjects: 72
Study 26867863 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (control group)
Number of subjects: 72
Study 26867863 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time medication monitoring
Number of subjects: 72
Study 26867863 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time medication monitoring and standard-of-care
Number of subjects: 72
Study 24507481 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Activities Program (TAP)
Number of subjects: 180
Study 24507481 — intervention group
Group type: COMPARATOR
Intervention: Phone-based education sessions (Control)
Number of subjects: 180
Study 22729797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively oriented behavioural rehabilitation in combination with Qigong
Number of subjects: 107
Study 22729797 — intervention group
Group type: COMPARATOR
Intervention: Qigong alone
Number of subjects: 107
Study 21218677 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored activity pacing intervention
Number of subjects: 32
Study 21218677 — intervention group
Group type: COMPARATOR
Intervention: General activity pacing intervention
Number of subjects: 32
Study 18496321 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric handgrip training (IHG) for 8 weeks
Number of subjects: 49
Study 15705369 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-antagonist
Number of subjects: 80
Study 15705369 — intervention group
Group type: COMPARATOR
Intervention: GnRH-agonist
Number of subjects: 80
Study 12847369 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct end‐to‐end repair
Number of subjects: 23
Study 12847369 — intervention group
Group type: COMPARATOR
Intervention: Overlapping sphincter repair
Number of subjects: 23
Study 10596247 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Family Systems Therapy (BFST)
Number of subjects: 37
Study 10596247 — intervention group
Group type: COMPARATOR
Intervention: Ego‐Oriented Individual Therapy (EOIT)
Number of subjects: 37
Study 8695600 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch from potato (17-30 g/d)
Number of subjects: 12
Study 8695600 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch from banana (17-30 g/d)
Number of subjects: 12
Study 8695600 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch from wheat (17-30 g/d)
Number of subjects: 12
Study 8695600 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch from maize (17-30 g/d)
Number of subjects: 12
Study 8695600 — intervention group
Group type: COMPARATOR
Intervention: Bran NSP (18.4 g NSP from bran/d)
Number of subjects: 12
Study 8695600 — intervention group
Group type: EXPERIMENTAL
Intervention: All forms of resistant starch
Number of subjects: 12
Study 8695600 — intervention group
Group type: EXPERIMENTAL
Intervention: RS2 (from potato and banana)
Number of subjects: 12
Study 8695600 — intervention group
Group type: EXPERIMENTAL
Intervention: RS3 (from wheat and maize)
Number of subjects: 12
Study 8695600 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch
Number of subjects: 12
Study 1917046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous penicillin G sodium (PG) 400,000‐500,000 I.U./kg/day for 14 days
Number of subjects: 23
Study 1917046 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone 75‐93 mg/kg/day for 14 days
Number of subjects: 23
Study 6627213 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 96
Study 6627213 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin combinations
Number of subjects: 96
Study 6627213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloleucine
Number of subjects: 96
Study 6627213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 96
Study 6627213 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Adriamycin combinations
Number of subjects: 96
Study 6627213 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover therapy (Adriamycin)
Number of subjects: 96
Study 6627213 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin treated patients
Number of subjects: 96
Study 6627213 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 96
Study 6627213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders
Number of subjects: 96
Study 6627213 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire series
Number of subjects: 96
Study 6627213 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with abdominal mesothelioma
Number of subjects: 96
Study 6627213 — intervention group
Group type: EXPERIMENTAL
Intervention: South African patients
Number of subjects: 96
Study 30959882 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive screwing task on day 1
Number of subjects: 57
Study 30959882 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive screwing task on day 2
Number of subjects: 57
Study 30959882 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive screwing task (extensor digitorum and biceps brachii)
Number of subjects: 57
Study 30959882 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive screwing task (flexor carpi radialis and triceps brachii)
Number of subjects: 57
Study 30959882 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive screwing task
Number of subjects: 57
Study 29920736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg + Probenecid 500 mg every 6 h from days 1 to 4
Number of subjects: 0
Study 29920736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg + Cimetidine 400 mg every 6 h from days 1 to 4
Number of subjects: 0
Study 29920736 — intervention group
Group type: COMPARATOR
Intervention: Mirogabalin 15 mg alone
Number of subjects: 0
Study 27422406 — intervention group
Group type: EXPERIMENTAL
Intervention: CFNB/SAMO group (continuous femoral nerve block with mini-dose spinal morphine)
Number of subjects: 68
Study 27422406 — intervention group
Group type: COMPARATOR
Intervention: CFNB/SA group (continuous femoral nerve block with spinal anesthesia)
Number of subjects: 68
Study 24814858 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5mg daily) and vitamin B12 (500 μg twice daily) for 12 weeks
Number of subjects: 72
Study 24814858 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (control group)
Number of subjects: 72
Study 22574583 — intervention group
Group type: EXPERIMENTAL
Intervention: QSDCMM combined with rehabilitation training
Number of subjects: 90
Study 22574583 — intervention group
Group type: COMPARATOR
Intervention: Western medicine treatment group (Chinese medicine placebo, Western medicine, and rehabilitation)
Number of subjects: 90
Study 22574583 — intervention group
Group type: COMPARATOR
Intervention: Control group (Chinese medicine placebo and rehabilitation)
Number of subjects: 90
Study 21344827 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B Pulsonic sonic toothbrush
Number of subjects: 129
Study 21344827 — intervention group
Group type: COMPARATOR
Intervention: ADA reference manual toothbrush
Number of subjects: 129
Study 17913672 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 119
Study 17913672 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 119
Study 16061122 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PAD (ABI<0.9)
Number of subjects: 0
Study 16061122 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (ABI>1)
Number of subjects: 0
Study 11777104 — intervention group
Group type: EXPERIMENTAL
Intervention: High-standardization CBT
Number of subjects: 252
Study 11777104 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-standardization CBT
Number of subjects: 252
Study 11777104 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 252
Study 11777104 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (High-standardization CBT, Low-standardization CBT, Treatment as usual)
Number of subjects: 252
Study 9610341 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost low dose (LD) 100 micrograms bid for 8 weeks
Number of subjects: 319
Study 9610341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 9610341 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost high dose (HD) 200 micrograms bid for 8 weeks
Number of subjects: 319
Study 9610341 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost low dose (LD) and high dose (HD)
Number of subjects: 319
Study 7923253 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA administered within 6 to 24 hours after onset of symptoms
Number of subjects: 100
Study 7923253 — intervention group
Group type: COMPARATOR
Intervention: Control group (no thrombolytic agent)
Number of subjects: 100
Study 3288479 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose bromocriptine
Number of subjects: 128
Study 3288479 — intervention group
Group type: COMPARATOR
Intervention: L-dopa
Number of subjects: 128
Study 4627050 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intragastric milk feeds (60 ml/kg/24 hr to 300 ml/kg/24 hr over 9 days) using either expressed human breast milk or SMA-S26.
Number of subjects: 66
Study 4627050 — intervention group
Group type: EXPERIMENTAL
Intervention: SMA-S26 (a proprietary low-protein adapted cows' milk)
Number of subjects: 66
Study 4627050 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-cream Regal milk (partly-skimmed evaporated cows' milk)
Number of subjects: 66
Study 30838664 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood
Number of subjects: 2964
Study 30838664 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell concentrates (RCC)
Number of subjects: 2964
Study 30838664 — intervention group
Group type: EXPERIMENTAL
Intervention: Packed cells
Number of subjects: 2964
Study 30838664 — intervention group
Group type: COMPARATOR
Intervention: Training intervention
Number of subjects: 2964
Study 30838664 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage duration
Number of subjects: 2964
Study 30838664 — intervention group
Group type: COMPARATOR
Intervention: Initial audit
Number of subjects: 2964
Study 30838664 — intervention group
Group type: COMPARATOR
Intervention: Third audit post-training
Number of subjects: 2964
Study 30135830 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended computer- and multimedia-supported psychoeducational group intervention
Number of subjects: 46
Study 27695894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intensive care recovery program plus standard care
Number of subjects: 386
Study 27695894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intensive care recovery program
Number of subjects: 386
Study 27695894 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 386
Study 24422887 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 8 weeks
Number of subjects: 273
Study 24422887 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory-based genomic studies
Number of subjects: 273
Study 23019303 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1000 mg i.m. injection followed by 500 mg injection every 6 weeks
Number of subjects: 36
Study 23019303 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) + levonorgestrel (LNG) 250 μg orally daily
Number of subjects: 36
Study 23019303 — intervention group
Group type: COMPARATOR
Intervention: Testosterone treatment in cynomolgus monkeys
Number of subjects: 36
Study 19413375 — intervention group
Group type: EXPERIMENTAL
Intervention: Early headgear (HG) treatment
Number of subjects: 68
Study 19413375 — intervention group
Group type: COMPARATOR
Intervention: Minor interceptive procedures
Number of subjects: 68
Study 17349681 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once daily)
Number of subjects: 0
Study 17349681 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (88 microg, 2 puffs twice daily)
Number of subjects: 0
Study 15072107 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 613
Study 15072107 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 613
Study 15072107 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (600 mg/day)
Number of subjects: 613
Study 15072107 — intervention group
Group type: COMPARATOR
Intervention: Valproate (1250 mg/day)
Number of subjects: 613
Study 11511432 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan (5, 20, 50, 100 mg h(−1))
Number of subjects: 38
Study 11511432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 11511432 — intervention group
Group type: COMPARATOR
Intervention: Nitrate vasodilators or nesiritide
Number of subjects: 38
Study 9062499 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly T4 therapy (7 times the normal daily dose)
Number of subjects: 12
Study 8164211 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted sphygmomanometer
Number of subjects: 33
Study 8164211 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorometer
Number of subjects: 33
Study 8164211 — intervention group
Group type: EXPERIMENTAL
Intervention: Penny & Giles myometer
Number of subjects: 33
Study 8164211 — intervention group
Group type: COMPARATOR
Intervention: Control group (no low back pain)
Number of subjects: 33
Study 3518556 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg aerosolized verapamil
Number of subjects: 0
Study 3518556 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg aerosolized verapamil
Number of subjects: 0
Study 3518556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30465488 — intervention group
Group type: EXPERIMENTAL
Intervention: Allied Health Leadership Development Program (n=16)
Number of subjects: 16
Study 30465488 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=17)
Number of subjects: 16
Study 27567447 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of stimulant medication
Number of subjects: 87
Study 24794763 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis alone (n=17)
Number of subjects: 21
Study 24794763 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthrocentesis with triamcinolone hexacetonide (n=21)
Number of subjects: 21
Study 24794763 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 21
Study 22932717 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 (200 mg twice daily)
Number of subjects: 301
Study 22932717 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (160 mg twice daily)
Number of subjects: 301
Study 22932717 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696
Number of subjects: 301
Study 22932717 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 301
Study 20695686 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral caffeine (250 mg/70 kg)
Number of subjects: 14
Study 20695686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17968001 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 drug administered at bedtime
Number of subjects: 250
Study 17968001 — intervention group
Group type: COMPARATOR
Intervention: All drugs taken on awakening
Number of subjects: 250
Study 16970086 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Capsule (FC) and Quxie Capsule (QC)
Number of subjects: 101
Study 16970086 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 101
Study 12936975 — intervention group
Group type: COMPARATOR
Intervention: Single doses of posaconazole oral tablets (50 to 1200 mg)
Number of subjects: 103
Study 12936975 — intervention group
Group type: COMPARATOR
Intervention: Posaconazole oral tablets (50 to 400 mg) twice daily for 14 days
Number of subjects: 103
Study 12936975 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole (all doses)
Number of subjects: 103
Study 10817713 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 295
Study 10817713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 9345411 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 0
Study 8508331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 151
Study 8508331 — intervention group
Group type: COMPARATOR
Intervention: Control (no fish oil supplementation)
Number of subjects: 151
Study 8508331 — intervention group
Group type: COMPARATOR
Intervention: Visual assessment
Number of subjects: 151
Study 8508331 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative computer analysis
Number of subjects: 151
Study 3555042 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg twice daily)
Number of subjects: 61
Study 3555042 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (2 g three times daily)
Number of subjects: 61
Study 31840739 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterargument invitation letters
Number of subjects: 6313
Study 31840739 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunk costs invitation letters
Number of subjects: 6313
Study 31840739 — intervention group
Group type: COMPARATOR
Intervention: Control (standard invitation)
Number of subjects: 6313
Study 29406427 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-L (aerobic before low-intensity resistance training)
Number of subjects: 60
Study 29406427 — intervention group
Group type: EXPERIMENTAL
Intervention: RA-L (aerobic after low-intensity resistance training)
Number of subjects: 60
Study 29406427 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-M (aerobic before moderate-intensity resistance training)
Number of subjects: 60
Study 29406427 — intervention group
Group type: EXPERIMENTAL
Intervention: RA-M (aerobic after moderate-intensity resistance training)
Number of subjects: 60
Study 29406427 — intervention group
Group type: COMPARATOR
Intervention: CON (nonintervention control)
Number of subjects: 60
Study 27335220 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg yohimbine
Number of subjects: 118
Study 27335220 — intervention group
Group type: COMPARATOR
Intervention: 0.15 mg clonidine
Number of subjects: 118
Study 27335220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 27335220 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 118
Study 24508328 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced walking on a treadmill (TM)
Number of subjects: 12
Study 24508328 — intervention group
Group type: EXPERIMENTAL
Intervention: Table tennis played continuously against the iPong robot (TT)
Number of subjects: 12
Study 24508328 — intervention group
Group type: COMPARATOR
Intervention: Rest (CON)
Number of subjects: 12
Study 22267390 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT (High-Intensity Interval Training) - 6 × 3-min at 90% Vo(2max) with recovery periods at 50% Vo(2max)
Number of subjects: 10
Study 22267390 — intervention group
Group type: COMPARATOR
Intervention: CONT (Continuous Running) - 50-min continuous running at 70% Vo(2max)
Number of subjects: 10
Study 19574172 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate 500 mg twice daily for 3 months
Number of subjects: 2
Study 19574172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 17319414 — intervention group
Group type: EXPERIMENTAL
Intervention: Squatting position (Group A)
Number of subjects: 200
Study 17319414 — intervention group
Group type: COMPARATOR
Intervention: Supine position (Group B)
Number of subjects: 200
Study 15045505 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive exercise (unilateral biceps curls to exhaustion)
Number of subjects: 0
Study 15045505 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter exercise period (unilateral biceps curls for 25% of the time to exhaustion)
Number of subjects: 0
Study 15045505 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaustive exercise (unilateral biceps curls)
Number of subjects: 0
Study 15045505 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising limb (after exhaustive exercise)
Number of subjects: 0
Study 11560832 — intervention group
Group type: EXPERIMENTAL
Intervention: CT examinations for brain
Number of subjects: 10
Study 11560832 — intervention group
Group type: EXPERIMENTAL
Intervention: CT examinations for chest
Number of subjects: 10
Study 11560832 — intervention group
Group type: EXPERIMENTAL
Intervention: CT examinations for abdomen
Number of subjects: 10
Study 11560832 — intervention group
Group type: EXPERIMENTAL
Intervention: CT examinations for pelvis
Number of subjects: 10
Study 9484878 — intervention group
Group type: EXPERIMENTAL
Intervention: grepafloxacin 400 mg once daily
Number of subjects: 32
Study 9484878 — intervention group
Group type: EXPERIMENTAL
Intervention: grepafloxacin 600 mg once daily
Number of subjects: 32
Study 9484878 — intervention group
Group type: EXPERIMENTAL
Intervention: ciprofloxacin 500 mg bd
Number of subjects: 32
Study 9484878 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 8049997 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Number of subjects: 0
Study 8049997 — intervention group
Group type: EXPERIMENTAL
Intervention: Selected nonrandomized series
Number of subjects: 0
Study 2455149 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50-100 mg/day)
Number of subjects: 12
Study 2455149 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (160-240 mg/day)
Number of subjects: 12
Study 28988687 — intervention group
Group type: EXPERIMENTAL
Intervention: Orantinib (200 mg, twice per day)
Number of subjects: 889